These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34423721)

  • 1. Metabolic disorders and the risk of cholangiocarcinoma.
    Ghidini M; Ramai D; Facciorusso A; Singh J; Tai W; Rijavec E; Galassi B; Grossi F; Indini A
    Expert Rev Gastroenterol Hepatol; 2021 Sep; 15(9):999-1007. PubMed ID: 34423721
    [No Abstract]   [Full Text] [Related]  

  • 2. Diabetes mellitus: Possible risk and promoting factors of cholangiocarcinoma: Association of diabetes mellitus and cholangiocarcinoma.
    Saengboonmee C; Seubwai W; Wongkham C; Wongkham S
    Cancer Epidemiol; 2015 Jun; 39(3):274-8. PubMed ID: 25910864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis.
    Clements O; Eliahoo J; Kim JU; Taylor-Robinson SD; Khan SA
    J Hepatol; 2020 Jan; 72(1):95-103. PubMed ID: 31536748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of nonalcoholic fatty liver disease and liver cancer.
    Schulz PO; Ferreira FG; Nascimento Mde F; Vieira A; Ribeiro MA; David AI; Szutan LA
    World J Gastroenterol; 2015 Jan; 21(3):913-8. PubMed ID: 25624725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk biomarkers for assessment and chemoprevention of liver fluke-associated cholangiocarcinoma.
    Yongvanit P; Pinlaor S; Loilome W
    J Hepatobiliary Pancreat Sci; 2014 May; 21(5):309-15. PubMed ID: 24408859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obesity and cholangiocarcinoma: A review of epidemiological and molecular associations.
    Osataphan S; Mahankasuwan T; Saengboonmee C
    J Hepatobiliary Pancreat Sci; 2021 Dec; 28(12):1047-1059. PubMed ID: 34053180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roles of liver fluke infection as risk factor for cholangiocarcinoma.
    Sithithaworn P; Yongvanit P; Duenngai K; Kiatsopit N; Pairojkul C
    J Hepatobiliary Pancreat Sci; 2014 May; 21(5):301-8. PubMed ID: 24408775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology of cholangiocarcinoma.
    Bergquist A; von Seth E
    Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):221-32. PubMed ID: 25966423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical presentation, risk factors and staging systems of cholangiocarcinoma.
    Plentz RR; Malek NP
    Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):245-52. PubMed ID: 25966425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Control of Opisthorchis viverrini infection for cholangiocarcinoma prevention].
    Buisson Y
    Bull Soc Pathol Exot; 2017 Feb; 110(1):61-67. PubMed ID: 28105582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis.
    Wongjarupong N; Assavapongpaiboon B; Susantitaphong P; Cheungpasitporn W; Treeprasertsuk S; Rerknimitr R; Chaiteerakij R
    BMC Gastroenterol; 2017 Dec; 17(1):149. PubMed ID: 29216833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholangiocarcinoma: Epidemiology and risk factors.
    Khan SA; Tavolari S; Brandi G
    Liver Int; 2019 May; 39 Suppl 1():19-31. PubMed ID: 30851228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of comorbidity between Opisthorchis viverrini infection and diabetes mellitus in the development of cholangiocarcinoma among a high-risk population, northeastern Thailand.
    Thinkhamrop K; Khuntikeo N; Laohasiriwong W; Chupanit P; Kelly M; Suwannatrai AT
    PLoS Negl Trop Dis; 2021 Sep; 15(9):e0009741. PubMed ID: 34543283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subtle to severe hepatobiliary morbidity in Opisthorchis viverrini endemic settings in southern Laos.
    Ayé Soukhathammavong P; Rajpho V; Phongluxa K; Vonghachack Y; Hattendorf J; Hongvanthong B; Rasaphon O; Sripa B; Akkhavong K; Hatz C; Odermatt P
    Acta Trop; 2015 Jan; 141(Pt B):303-9. PubMed ID: 25275346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synopsis.
    Khuntikeo N; Andrews RH; Petney TN; Khan SA
    Recent Results Cancer Res; 2023; 219():361-367. PubMed ID: 37660340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic and transcriptional alterations of cholangiocarcinoma.
    Ito T; Sakurai-Yageta M; Goto A; Pairojkul C; Yongvanit P; Murakami Y
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):380-7. PubMed ID: 24532422
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Treeriya R; Ho PN; Titapun A; Klanrit P; Suksawat M; Kulthawatsiri T; Sirirattanakul S; Loilome W; Namwat N; Wangwiwatsin A; Chamadol N; Khuntikeo N; Phetcharaburanin J
    PeerJ; 2023; 11():e15386. PubMed ID: 37187520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory pathways and cholangiocarcinoma risk mechanisms and prevention.
    Cadamuro M; Strazzabosco M
    Adv Cancer Res; 2022; 156():39-73. PubMed ID: 35961707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant GLUT1 Expression Is Associated With Carcinogenesis and Progression of Liver Fluke-associated Cholangiocarcinoma.
    Thamrongwaranggoon U; Sangkhamanon S; Seubwai W; Saranaruk P; Cha'on U; Wongkham S
    In Vivo; 2021; 35(1):267-274. PubMed ID: 33402473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transplantation for cholangiocarcinoma.
    Masuoka HC; Rosen CB
    Clin Liver Dis; 2011 Nov; 15(4):699-715. PubMed ID: 22032524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.